Rosenbloom Joshua I, Wellenius Gregory A, Mukamal Kenneth J, Mittleman Murray A
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Am Heart J. 2009 Nov;158(5):867-73. doi: 10.1016/j.ahj.2009.08.019. Epub 2009 Sep 24.
Symptoms of anxiety are associated with increased risk of coronary artery disease and potentially poor prognosis among patients with existing coronary artery disease, but whether symptoms of anxiety influence atherosclerotic progression among such patients is uncertain. Accordingly, we evaluated the hypotheses that symptoms of anxiety are associated with adverse clinical outcomes and progression of atherosclerosis among individuals with previous coronary artery bypass graft (CABG) surgery and saphenous vein grafts enrolled in the Post-CABG Trial.
The Post-CABG Trial randomized patients with a history of CABG surgery to either aggressive or moderate lipid lowering and to either warfarin or placebo. Patients were followed up for clinical end points and coronary angiography was conducted at enrollment and after a median follow-up of 4.3 years. Anxiety symptoms were assessed at enrollment using the state portion of the Spielberger State-Trait Anxiety Inventory (STAI) in 1317 patients.
In models adjusting for age, sex, race, treatment assignment and years since CABG surgery, a STAI score > or =40 was positively associated with risk of death or myocardial infarction (MI) (OR 1.55, 95% CI 1.01-2.36, P = .044). This association was attenuated slightly when depressive symptoms were included in the model, but lost statistical significance (P = .11). There was a dose-response relationship between STAI score and risk of death or MI. There was no association between self-reported anxiety and atherosclerotic progression of grafts.
Anxiety symptoms are associated with increased risk of death or MI among patients with saphenous vein grafts, but this risk does not appear to be mediated by more extensive atherosclerotic progression.
焦虑症状与冠状动脉疾病风险增加相关,且在已有冠状动脉疾病的患者中可能预后较差,但焦虑症状是否会影响此类患者的动脉粥样硬化进展尚不确定。因此,我们评估了以下假设:在参加冠状动脉搭桥术(CABG)试验的既往有CABG手术和隐静脉移植的个体中,焦虑症状与不良临床结局和动脉粥样硬化进展相关。
CABG试验将有CABG手术史的患者随机分为强化降脂或中度降脂组,以及华法林组或安慰剂组。对患者进行临床终点随访,并在入组时和中位随访4.3年后进行冠状动脉造影。使用斯皮尔伯格状态-特质焦虑量表(STAI)的状态部分对1317例患者入组时的焦虑症状进行评估。
在调整年龄、性别、种族、治疗分组和CABG手术后年限的模型中,STAI评分≥40与死亡或心肌梗死(MI)风险呈正相关(OR 1.55,95%CI 1.01-2.36,P = 0.044)。当模型中纳入抑郁症状时,这种关联略有减弱,但失去统计学意义(P = 0.11)。STAI评分与死亡或MI风险之间存在剂量反应关系。自我报告的焦虑与移植血管的动脉粥样硬化进展之间无关联。
焦虑症状与隐静脉移植患者的死亡或MI风险增加相关,但这种风险似乎不是由更广泛的动脉粥样硬化进展介导的。